MedTrace Logo

Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia

NCT00956332 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-03-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and activity of two doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with chronic critical limb ischemia.

Conditions

  • Peripheral Arterial Disease
  • Peripheral Vascular Disease
  • Critical Limb Ischemia

Interventions

BIOLOGICAL

MultiGeneAngio

Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

BIOLOGICAL

MultiGeneAngio

Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

Sponsors & Collaborators

  • MultiGene Vascular Systems Ltd.

    lead INDUSTRY

Principal Investigators

  • Sam L. Teichman, MD · Independent consultant

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-08-31
Completion
2026-05-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00956332 on ClinicalTrials.gov